London, United Kingdom--(Newsfile Corp. - September 5, 2025) - Edison issues report on Amoéba (PAR: ALMIB).
Amoéba is ready to launch its innovative and patented WmCM amoeba lysate active ingredient into the vast crop protection and anti-ageing skincare cosmetics markets. Excellent field trial results, combined with regulatory tailwinds, as consumers reduce their use of traditional chemical products, strongly support future growth. With key distribution partnerships in place, Amoéba should witness superior growth in the coming years. It has raised €9m in cash and executed a €5m debt-for-equity swap with support from key shareholder Nice & Green and distribution partner Koppert. We value Amoéba at €2.01 per share.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website.
www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
enquiries@edisongroup.com
+44 (0)20 3077 5700
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265308
SOURCE: Edison Group
